The US Department of Health and Human Services (HHS) announced SURPASS, a new five-year program to speed and expand clinical trials by integrating artificial intelligence and computational models. The initiative, launched through the Advanced Research Projects Projects Agency for Health (ARPA-H), is designed to move beyond sharply delineated trial phases and to accept ideas from cross-disciplinary teams spanning statistics, AI, clinical trial design, operations, and regulation. HHS did not disclose a specific funding level in the initial announcement and has not yet detailed how much added flexibility or resources trial participants may receive. The agency’s stated goal is to improve trial efficiency while preserving regulatory rigor. For biotech developers, SURPASS signals a near-term shift in how sponsors may structure evidence generation, with more emphasis on simulation-augmented and real-time adaptive trial designs that can compress timelines without relying solely on traditional phase-based gating.